{"id":"shr-2004-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR-2004 injection works by binding to PD-1, preventing its interaction with its ligands PD-L1 and PD-L2, and thereby enhancing T-cell activation and proliferation. This leads to an anti-tumor immune response. The exact mechanism of action may involve additional pathways and interactions.","oneSentence":"SHR-2004 injection is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:27.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06825416","phase":"PHASE3","title":"A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2025-03-16","conditions":"Prevention of Arterial and Venous Thrombosis","enrollment":1166},{"nctId":"NCT06220123","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-02-16","conditions":"Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","enrollment":225},{"nctId":"NCT05752461","phase":"PHASE2","title":"SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2023-04-12","conditions":"Prevention of Venous Thromboembolism After Knee Arthroplasty","enrollment":353},{"nctId":"NCT06280768","phase":"PHASE1","title":"Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation","status":"UNKNOWN","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-03-01","conditions":"Atrial Fibrillation","enrollment":48},{"nctId":"NCT05369767","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects","status":"UNKNOWN","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2022-05-24","conditions":"Prevention of Arterial and Venous Thrombosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-2004 injection","genericName":"SHR-2004 injection","companyName":"Beijing Suncadia Pharmaceuticals Co., Ltd","companyId":"beijing-suncadia-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-2004 injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}